Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial.

被引：0
|
作者：
Burotto, Mauricio
Powles, Thomas
Escudier, Bernard
Apolo, Andrea B.
Bourlon, Maria Teresa
Shah, Amishi Yogesh
Suarez, Cristina
Porta, Camillo
Barrios, Carlos H.
Richardet, Martin
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
George, Saby
Scheffold, Christian
Wang, Peter
Fedorov, Viktor
Motzer, Robert J.
Choueiri, Toni K.
机构：
[1] Bradford Hill Clin Res Ctr, Santiago, Chile
[2] Barts Canc Ctr, London, England
[3] Royal Free London NHS Fdn Trust, London, England
[4] Gustave Roussy, Villejuif, France
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med Nutr, Mexico City, Mexico
[7] MD Anderson Canc Ctr, Houston, TX USA
[8] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[9] Univ Pavia, Pavia, Italy
[10] Ctr Pesquisa Oncol, Porto Alegre, Brazil
[11] Inst Oncol Cordoba, dn Richardet Longo, Cordoba, Argentina
[12] Westmead Hosp, Sydney, NSW, Australia
[13] Macquarie Univ, Sydney, NSW, Australia
[14] Univ Colorado, Canc Ctr, Anschutz Med Campus, Aurora, CO USA
[15] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[16] Eberhard Karls Univ Tubingen, Tubingen, Germany
[17] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
[18] Exelixis Inc, Alameda, CA USA
[19] Bristol Myers Squibb, Princeton, NJ USA
[20] Mem Sloan Kettering Canc Ctr, New York, NY USA
[21] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, Boston, MA USA
[22] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
603
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Atkins, Michael B.
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian, I
    Jiang, Ruiyun
    Federov, Viktor
    Lee, Chung-Wei
    Desilva, Heshani
    Tannir, Nizar M.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S17 - S18
  • [22] Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)
    Mantia, Charlene
    Jegede, Opeyemi
    Viray, Hollis
    Atkins, Michael B.
    Rosenblatt, Lisa
    Yin, Xin
    McDermott, David F.
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    ESMO OPEN, 2020, 5 (06)
  • [24] ASCO-GU: 2-Year Follow-up of the CheckMate-9ER Study: Sustained Treatment Benefit with First-line Therapy of advanced Renal Cell Carcinoma with Cabozantinib plus Nivolumab versus Sunitinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [25] Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
    Motzer, Robert J.
    Choueiri, Toni K.
    Powles, Thomas
    Burotto, Mauricio
    Bourlon, Maria Teresa
    Hsieh, James J.
    Maruzzo, Marco
    Shah, Amishi Yogesh
    Suarez, Cristina
    Barrios, Carlos H.
    Richardet, Martin Eduardo
    Porta, Camillo
    Goh, Jeffrey C.
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Gupta, Saurabh
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Tannir, N. M.
    McDermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Plimack, E. R.
    Porta, C. G.
    George, S.
    Powles, T. B.
    Donskov, F.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M-O.
    Tomita, Y.
    Rini, B. I.
    McHenry, M. B.
    Lee, C-W.
    Escudier, B.
    ANNALS OF ONCOLOGY, 2021, 32 : S685 - S687
  • [27] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Plain language summary of quality of life in CheckMate 9ER: Cabozantinib plus nivolumab in advanced renal cell carcinoma
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven I.
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Choueiri, Toni K.
    Apolo, Andrea B.
    FUTURE ONCOLOGY, 2025, 21 (02) : 181 - 194
  • [29] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [30] Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO plus CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.
    Cella, David
    Choueiri, Toni K.
    Blum, Steven I.
    Ejzykowicz, Flavia
    Wallace, Joel
    Zhang, Joshua
    Simsek, Burcin
    Ivanescu, Cristina
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345